1 |
M. C. Nawijn, A. Alendar, and A. Berns, "For better or for worse: the role of Pim oncogenes in tumorigenesis", Nat. Rev. Cancer, Vol. 11, pp. 23-34, 2011.
DOI
|
2 |
J. D. Feldman, L. Vician, M. Crispino, G. Tocco, M. Baudry, and H. R. Herschman, "Seizure activity induces PIM-1 expression in brain", J. Neurosci. Res., Vol. 53, pp. 502-509, 1998.
DOI
|
3 |
L. Brault, C. Gasser, F. Bracher, K. Huber, S. Knapp, and J. Schwaller, "PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers", Haematologica, Vol. 95, pp. 1004-1015, 2010.
DOI
|
4 |
T. Moroy, S. Verbeek, A. Ma, P. Achacoso, A. Berns, and F. Alt, "E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice", Oncogene, Vol. 6, pp. 1941-1948, 1991.
|
5 |
H. T. Cuypers, G. Selten, A. Berns, and A. H. M. Geurts van Kessel, "Assignment of the human homologue of Pim-1, a mouse gene implicated in leukemogenesis, to the pter-q12 region of chromosome 6", Human Genetics, Vol. 72, pp. 262-265, 1986.
DOI
|
6 |
Z. P. Wang, N. Bhattacharya, M. Weaver, K. Petersen, M. Meyer, L. Gapter, and N. S. Magnuson, "Pim- 1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis", J. Vet. Sci., Vol. 2, pp. 167-179, 2001.
|
7 |
G. Selten, H. T. Cuypers, and A. Berns, "Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas", EMBO J., Vol. 4, pp. 1793-1798, 1985.
|
8 |
W. Chen, A. R. Kumar, W. A. Hudson, Q. Li, B. Wu, R. A. Staggs, E. A. Lund, T. N. Sam, and J. H. Kersey, "Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells", Cancer Cell, Vol. 13, pp. 432-440, 2008.
DOI
|
9 |
B. G. Bajaj, S. C. Verma, K. Lan, M. A. Cotter, Z. L. Woodman, and E. S. Robertson, "KSHV encoded LANA upregulates Pim-1 and is a substrate for its kinase activity", Virology, Vol. 351, pp. 18-28, 2006.
DOI
|
10 |
E. M. Rainio, H. Ahlfors, K. L. Carter, M. Ruuska, S. Matikainen, E. Kieff, et al., "Pim kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity", Virology, Vol. 333, pp. 201-206, 2005.
DOI
|
11 |
L. Pasqualucci, P. Neumeister, T. Goossens, G. Nanjangud, R. S. K. Chaganti, R. Kuppers, R. Dalla-Favera, "Hypermutation of multiple proto-oncogenes in B-cell diffuse large cell lymphomas", Nature, Vol. 412, pp. 341-346, 2001.
DOI
|
12 |
S. Guo, X. Mao, J. Chen, B. Huang, C. Jin, Z. Xu, and S. Qiu, "Overexpression of Pim-1 in bladder cancer", J. Exp. Clin. Cancer Res., Vol. 29, pp. 161-167, 2010.
DOI
|
13 |
W. W. Chen, D. C. Chan, C. Donald, M. B. Lilly, and A. S. Kraft, "Pim family kinases enhance tumor growth of prostate cancer cells", Mol. Cancer Res., Vol. 3, pp. 443-451, 2005.
DOI
|
14 |
J. Kim, M. Roh, and S. A. Abdulkadir, "Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity", BMC Cancer, Vol. 10, pp. 248-262, 2010.
DOI
|
15 |
M. E. Nga, N. N. M. Swe, K. T. Chen, L. Shen, M. B. Lilly, S. P. Chan, M. Salto-Tellez, and K. Das, "PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications", Int. J. Exp. Pathol., Vol. 91, pp. 34-43, 2010.
DOI
|
16 |
P. K. Balasubramanian and S. J. Cho, "HQSAR analysis on novel series of 1-(4-phenylpiperazin-1-yl-2-(1H-Pyrazol-1-yl) ethanone derivatives targeting CCR1", J. Chosun Natural Sci., Vol. 6, pp. 163-169, 2013.
DOI
|
17 |
N. Shah, B. Pang, K. G. Yeoh, S. Thorn, C. S. Chen, M. B. Lilly, et al., "Potential roles for the PIM1 kinase in human cancer-a molecular and therapeutic appraisal", Eur. J. Cancer, Vol. 44, pp. 2144-2151, 2008.
DOI
|
18 |
M. Bachmann and T. Moroy, "The serine/threonine kinase Pim-1", Int. J. Biochem. Cell Biol., Vol. 37, pp. 726-730, 2005.
DOI
|
19 |
P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "A CoMFA study of phenoxypyridine-based JNK3 inhibitors using various partial charge schemes", J. Chosun Natural Sci., Vol. 7, pp. 45-49, 2014.
DOI
|
20 |
A. Balupuri and S. J. Cho, "Exploration of the binding mode of indole derivatives as potent HIV-1 inhibitors using molecular docking simulations", J. Chosun Natural Sci., Vol. 6, pp. 138-142, 2013.
DOI
|
21 |
C. G. Gadhe and S. J. Cho, "Importance of silicon atom in the drug design process", J. Chosun Natural Sci., Vol. 5, pp. 229-232, 2012.
DOI
|
22 |
S. J. Cho, "The importance of halogen bonding: A tutorial", J. Chosun Natural Sci., Vol. 5, pp. 195-197, 2012.
DOI
|
23 |
R. P. Wurz, C. Sastri, D. C. D'Amico, B. Herberich, C. L. M. Jackson, L. H. Pettus, A. S. Tasker, B. Wu, N. Guerrero, J. R. Lipford, J. T. Winston, Y. Yang, P. Wang, Y. Nguyen, K. L. Andrews, X. Huang, M. R. Lee, C. Mohr, J. D. Zhang, D. L. Reid, Y. Xu, Y. Zhou, and H.-L. Wang, "Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors." Bioorg. Med. Chem. Lett., Vol. 26, pp. 5580-5590, 2016.
DOI
|
24 |
SYBYLx2.1, Tripos International, 1699 South Hanley Road, St. Louis, Missouri, 63144, USA.
|
25 |
P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "3D QSAR studies of Mks (TTK) kinase inhibitors based on CoMFA", Vol. 9, pp. 113-120, 2016.
DOI
|
26 |
R. D. Cramer, D. E. Patterson, and J. D. Bunce, "Comparative molecular field analysis (CoMFA). Effect of shape on binding of steroids to carrier proteins", J. Am. Chem. Soc., Vol. 110, pp. 5959-5967, 1988.
DOI
|
27 |
P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "3D QSAR study on pyrrolopyrimidines-based derivatives as LIM2 kinase inhibitors", J. Chosun Natural Sci., Vol. 8, pp. 285-292, 2015.
DOI
|